Form 4: Phibro Animal Health CEO Sells Shares Under 10b5-1 Plan

Phibro Animal Health's President and CEO, Jack Bendheim, and BFI Co., LLC, sold a total of 13,465 shares of Class A Common Stock in late January 2026 through a pre-arranged trading plan.

Summary

• Jack Bendheim, President and CEO, Director, and 10% Owner of Phibro Animal Health Corp (PAHC), along with BFI Co., LLC (also a 10% owner), reported sales of Class A Common Stock.
• A total of 6,772 shares were sold on January 29, 2026, at a weighted average price of $40.1192 per share, with prices ranging from $40.00 to $40.475.
• An additional 6,693 shares were sold on January 30, 2026, at a weighted average price of $40.0941 per share, with prices ranging from $40.00 to $40.365.
• These sales were executed pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC on May 30, 2025.
• Following these transactions, BFI Co., LLC indirectly holds 31,980 shares, and Jack Bendheim directly holds 16,840 shares of Class A Common Stock.
• Jack Bendheim exercises voting and dispositive power over BFI Co., LLC's holdings but disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event because the sales were conducted under a pre-arranged Rule 10b5-1 trading plan, which typically indicates personal financial planning rather than a reaction to new company-specific information.

Negatives

• The sale of shares by a key insider, even under a 10b5-1 plan, could be interpreted by some investors as a lack of conviction, though this is often a routine liquidity or diversification event.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that insider sales, particularly by high-ranking executives and significant shareholders, are closely watched by the market. However, sales executed under a Rule 10b5-1 trading plan, adopted well in advance of the transaction dates, are generally viewed as less indicative of management's immediate sentiment regarding the company's future prospects compared to unplanned, open-market sales. These plans are typically established for personal financial planning, such as diversification or liquidity.

Stakeholder Impact

• Shareholders may observe these insider sales as routine diversification or liquidity events given the pre-arranged 10b5-1 plan, rather than a signal of changing company fundamentals.

Key Dates

Keywords

Phibro Animal Health, PAHC, Jack Bendheim, Insider Sales, Form 4, 10b5-1 Plan, Executive Stock Sale, Animal Health